ロード中...
A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
Chimeric antigen receptor (CAR) T cells targeting CD19 have been successful treating patients with relapsed/refractory B cell acute lymphoblastic leukemia (ALL) and B cell lymphomas. However, relapse after CAR T cell therapy is still a challenge. In addition, preclinical and early clinical studies t...
保存先:
| 出版年: | Front Oncol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7058784/ https://ncbi.nlm.nih.gov/pubmed/32185132 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00262 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|